Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Codman Specialty Surgical | 1,019.6 | 1,025.2 | 894.8 | 996.2 | 963.9 | 720.3 | | 586.9 |
| Orthopedics & Tissue Technologies | | | | | 508.5 | 467.9 | | 295.8 |
| Other | 538.1 | 517.2 | 477.0 | 521.4 | | | | |
| Total revenues [+] | 1,557.7 | 1,542.4 | 1,371.9 | 1,517.6 | 1,472.4 | 1,188.2 | 992.1 | 882.7 |
| Products | | | | | | | | 882.7 |
| Revenue growth [+] | 1.0% | 12.4% | -9.6% | 3.1% | 23.9% | 19.8% | 12.4% | 10.8% |
| Codman Specialty Surgical | -0.6% | 14.6% | -10.2% | 3.3% | 33.8% | | | 5.8% |
| Orthopedics & Tissue Technologies | | | | | 8.7% | | | 22.3% |
| Cost of goods sold | 651.8 | 664.3 | 567.5 | 610.5 | 621.9 | 471.2 | 349.1 | 326.5 |
| Gross profit | 905.9 | 878.1 | 804.3 | 907.1 | 850.5 | 717.0 | 643.0 | 556.2 |
| Gross margin | 58.2% | 56.9% | 58.6% | 59.8% | 57.8% | 60.3% | 64.8% | 63.0% |
| Selling, general and administrative | 616.3 | 637.4 | 594.5 | 687.6 | 690.7 | 624.1 | 455.6 | 415.8 |
| Research and development | 101.2 | 93.1 | 77.4 | 79.6 | 78.0 | 63.5 | 58.2 | 50.9 |
| Other operating expenses | -50.5 | -49.6 | -18.9 | -18.8 | -29.2 | -15.3 | 13.9 | 10.0 |
| EBITDA [+] | 357.2 | 317.1 | 267.4 | 268.1 | 221.7 | 133.7 | 188.0 | 138.5 |
| EBITDA growth | 12.7% | 18.6% | -0.3% | 20.9% | 65.8% | -28.9% | 35.8% | 21.1% |
| EBITDA margin | 22.9% | 20.6% | 19.5% | 17.7% | 15.1% | 11.3% | 19.0% | 15.7% |
| Depreciation | 104.4 | 102.9 | 88.3 | 82.4 | 89.6 | 68.6 | 58.8 | 48.9 |
| EBITA | 252.8 | 214.1 | 179.1 | 185.7 | 132.2 | 65.2 | 129.2 | 89.5 |
| EBITA margin | 16.2% | 13.9% | 13.1% | 12.2% | 9.0% | 5.5% | 13.0% | 10.1% |
| Amortization of intangibles | 13.9 | 16.9 | 27.8 | 27.0 | 21.2 | 20.4 | 13.9 | 10.0 |
| EBIT [+] | 238.9 | 197.2 | 151.4 | 158.7 | 111.0 | 44.8 | 115.3 | 79.6 |
| EBIT growth | 21.1% | 30.3% | -4.6% | 43.0% | 147.7% | -61.2% | 44.9% | 17.3% |
| EBIT margin | 15.3% | 12.8% | 11.0% | 10.5% | 7.5% | 3.8% | 11.6% | 9.0% |
| Non-recurring items | | | | 64.9 | | | | |
| Interest expense, net [+] | 37.7 | 43.7 | 62.3 | 43.2 | 61.9 | 34.8 | 25.8 | 23.5 |
| Interest expense | 49.6 | 50.4 | 71.6 | 54.0 | 64.7 | 35.0 | 25.8 | 23.5 |
| Interest income | 11.9 | 6.7 | 9.3 | 10.8 | 2.8 | 0.3 | 0.0 | 0.0 |
| Other income (expense), net | 12.7 | 61.1 | 4.4 | 9.5 | 8.3 | 1.3 | 0.8 | 4.6 |
| Pre-tax income | 213.9 | 214.7 | 93.5 | 60.1 | 57.4 | 11.4 | 90.4 | 60.7 |
| Income taxes | 33.3 | 45.6 | -40.4 | 9.9 | -3.4 | -53.4 | 15.8 | 53.8 |
| Tax rate | 15.6% | 21.2% | | 16.5% | | | 17.5% | 88.7% |
| Net income | 180.6 | 169.1 | 133.9 | 50.2 | 60.8 | 64.7 | 74.6 | -3.5 |
| Net margin | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.4% | 7.5% | -0.4% |
| |
| Basic EPS [+] | $2.18 | $2.00 | $1.58 | $0.59 | $0.73 | $0.84 | $1.00 | $0.10 |
| Growth | 9.0% | 26.2% | 169.8% | -20.1% | -12.8% | -16.0% | 909.4% | -82.3% |
| Diluted EPS [+] | $2.16 | $1.98 | $1.57 | $0.58 | $0.72 | $0.82 | $0.94 | $0.10 |
| Growth | 9.3% | 25.9% | 170.7% | -19.8% | -11.5% | -13.1% | 880.6% | -82.6% |
| |
| Shares outstanding (basic) [+] | 83.0 | 84.7 | 84.7 | 85.6 | 82.9 | 76.9 | 74.4 | 69.0 |
| Growth | -2.0% | 0.1% | -1.2% | 3.4% | 7.8% | 3.4% | 7.8% | 6.4% |
| Shares outstanding (diluted) [+] | 83.5 | 85.5 | 85.2 | 86.5 | 84.0 | 79.1 | 79.2 | 71.4 |
| Growth | -2.3% | 0.3% | -1.5% | 3.0% | 6.2% | -0.1% | 11.0% | 8.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|